Navigation Links
Abbott Introduces Biothreat Assay for PLEX-ID™ System
Date:2/7/2011

WASHINGTON, Feb. 7, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it has introduced the PLEX-ID™ Biothreat Assay, which is designed to detect and distinguish 17 different biothreat pathogens.  This assay enables rapid and accurate detection of potentially dangerous microorganisms that could pose serious threats to human health, food, water and other resources.

"While public health officials concerned with bioterrorism and emerging infectious diseases are detecting known, conventional infectious agents, it's becoming very clear there is a need for broader detection and characterization of pathogens for  biodefense," said David Ecker, Ph.D., divisional vice president and general manager, of Abbott's Ibis Biosciences subsidiary.  "The PLEX-ID system's new biothreat assay will serve that need by identifying and quantifying, for non-diagnostic purposes, a broad set of pathogens including bacteria and families of viruses in humans and animals."

The PLEX-ID Biothreat Assay permits analysis of direct specimens, such as blood, water, food and air filter samples, and provides results in less than eight hours.  Seventeen different bioagents are targeted in the new test, including Bacillus anthracis, E. coli, salmonella, ebola virus, and avian influenza viruses.  PLEX-ID offers the unique capability to detect and identify these, and other, bacterial and viral biothreat agents while also differentiating similar organisms.    

Research on the biothreat assay was presented at the American Society for Microbiology Conference on Biodefense and Emerging Diseases.  In a poster presented at the conference, Abbott and the Midwest Research Institute reported that an independent evaluation of the PLEX-ID Biothreat Assay showed it provides highly sensitive and specific results for biothreat detection in environmental air sample analysis.  

The PLEX-ID system can perform identification and typing of expected and unknown microorganisms from direct specimens, which saves time while providing critical information without the need to grow the agent in culture first.  

About PLEX-ID

Currently intended for non-diagnostic use, PLEX-ID is the only high-throughput technology that offers rapid and broad identification, detailed genotyping and characterization, and recognition of emerging organisms.  The system employs a combination of molecular technologies, including polymerase chain reaction (PCR) for gene amplification and mass spectrometry analysis to rapidly characterize known and unknown organisms.  

It is designed to address a significant unmet need by providing test results in less than eight hours instead of three or more days required with current blood and tissue culture-based methods.

PLEX-ID is designed to identify a broad range of bacteria, viruses, fungi, certain parasites, and also provide information about drug resistance, virulence, and strain type.  Anticipated public health and biodefense applications include epidemiologic research and identification of emerging or previously unknown agents.  In addition, the system is being used for forensic characterization of human samples.

In 2009, PLEX-ID was recognized by both The Scientist and the Wall Street Journal as a top scientific innovation of the year.  The Scientist honored the system because it can detect and characterize a broad range of microorganisms in any given sample.  PLEX-ID was chosen as the Gold winner of the 2009 Wall Street Journal Technology Innovation Awards because it promises to alert health officials to new disease strains, may also guard against bio-terrorism, and enable hospitals to identify antibiotic-resistant bacteria in its environment.

Since its development in 2005, PLEX-ID technology has been deployed in 20 sites around the United States, including the Centers for Disease Control and Prevention and the U.S. Food and Drug Administration.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs nearly 90,000 people and markets its products in more than 130 countries.

Abbott information is available on the company's Web site at www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intelligent Medical Devices, Inc. (IMDx) Enters into an Agreement with Abbott for the Distribution of a Broad Menu of Molecular Tests
2. Partners In Health, Abbott and the Abbott Fund Unite to Combat Severe Childhood Malnutrition in Haiti
3. AstraZeneca and Abbott End License Agreement for the Development of CERTRIAD
4. Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico
5. Abbott Named One of Americas Most Generous Companies, Sets Company Records for Employee Giving
6. Abbott Remains on the Dow Jones Sustainability Indexes for the Sixth Consecutive Year in Recognition of Leading Corporate Citizenship Performance
7. Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa
8. Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
9. Abbott Again Recognized for Environmental Initiatives in Illinois
10. Abbott Statement: Abbott Provides Support for Cholera Relief Efforts in Haiti
11. Abbott to Voluntarily Withdraw Meridia® (Sibutramine) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)... April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) ... & Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... , Chief Executive Officer of the Company is scheduled to present ... Richard Bear and the Chairman of the Board, Tony ... ...
Breaking Medicine Technology:
(Date:4/28/2017)... SALT LAKE CITY, UTAH (PRWEB) , ... April ... ... Josée Côté as Account Manager for the North East region. Côté has 20+ ... operations and consulting. Prior to Phytomer, Côté worked with an array of high-end ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor that has ... presence to an educational purpose as the host of the “Informed” series. The program ... a recent episode, the series focuses on thyroid cancer. , Although thyroid cancer is ...
(Date:4/27/2017)... , ... April 27, 2017 , ... ... Insights in Incentives, Rewards, and Recognition: A Nudge Guide," a groundbreaking analysis of ... field. Offering practical takeaways to apply immediately to IRR programs, the report highlights ...
(Date:4/27/2017)... Neb. (PRWEB) , ... April 27, 2017 , ... ... was named the 2017 North American CAREGiverSM of the Year for her extraordinary ... selects one of its 60,000 North American professional caregivers for the prestigious award ...
(Date:4/27/2017)... GA (PRWEB) , ... April 27, 2017 , ... Are ... a tragic spike in water-related accidents and drownings during the summer. While most of ... is that these situations occur every day. Very few people are taking the time ...
Breaking Medicine News(10 mins):